MK-0249

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H24F3N3O2
Molecular Weight	431.4508
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(C(=O)N1C3=CC=C(OCCCN4CCCC4)C=C3)C(=CC=C2)C(F)(F)F

InChI

InChIKey=DDDZBLNULGDPGA-UHFFFAOYSA-N

InChI=1S/C23H24F3N3O2/c1-16-27-20-7-4-6-19(23(24,25)26)21(20)22(30)29(16)17-8-10-18(11-9-17)31-15-5-14-28-12-2-3-13-28/h4,6-11H,2-3,5,12-15H2,1H3

HIDE SMILES / InChI

Molecular Formula	C23H24F3N3O2
Molecular Weight	431.4508
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23523692 | https://www.ncbi.nlm.nih.gov/pubmed/23920422 | https://www.ncbi.nlm.nih.gov/pubmed/22901359

MK-0249 is a potent H3 receptor inverse agonist patented by Abbott Laboratories for treatment of cognitive deficits. MK-0249 demonstrates promising results in preclinical models of cognitive disorders. MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia ets. Unfortunately, MK-0249 failed to demonstrate efficacy in schizophrenia, mild-to-moderate Alzheimer's Disease, attention-deficit/hyperactivity disorder, and future development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.	2015-07	26084539
(11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists.	2014-01	24263088
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.	2012-05	22272611
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.	2011-07-14	21634396
Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.	2008-08-14	18598020

Patents

Sample Use Guides

In Vivo Use Guide

10mg once daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:43:33 GMT 2025` Edited by `admin` on `Mon Mar 31 21:43:33 GMT 2025`
Record UNII	KF50235Q04
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MK-0249

Common Name

English

MK0249

Preferred Name

English

2-METHYL-3-(4-(3-PYRROLIDIN-1-YLPROPOXY)PHENYL)-5-(TRIFLUOROMETHYL)QUINAZOLIN-4-ONE

Systematic Name

English

Code System Code Type Description

FDA UNII

KF50235Q04